

HOW TO GIVE | Contributions to the Shade Foundation Melanoma Research Fund at TGen can be made in a variety of ways:

Online | www.shadefoundation.org or www.helpngen.org

By Check | Make checks payable to the TGen Foundation and mail to the address below. *

By Visa or MasterCard | Please call the TGen Foundation, 602.343.8411 to charge your gift to your credit card, or contribute on-line by visiting www.helpngen.org. *

By Donating Non-Cash Gifts | TGen accepts non-cash gifts in the form of securities and other assets. Please contact the TGen Foundation at 602.343.8411 to contribute highly appreciated stock or other forms of financial assets.

Pledges | The TGen Foundation will accept a pledge that may be paid out over a period of time if you wish. Contact Christine Fleming at the TGen Foundation for a pledge form and to discuss the terms of your gift.


Make a Future Gift | You may consider including the Shade Foundation Melanoma Research Fund in your will or trust. If you do so, please notify the TGen Foundation so that appropriate recognition can be made for your generosity.

** Please remember to specify that your gift is in support of the Shade Foundation Melanoma Research Fund at TGen.*



400 N. 5th Street, Suite 1650
Phoenix, AZ 85004
Phone: (602) 343-TGEN (8436)
Fax: (602) 343-8441
www.helpngen.org

TGen is a non-profit 501.c.3 biomedical research institute, and all contributions are tax-deductible to the extent allowed by law. All donors will receive a formal acknowledgement and receipt for tax purposes.



SHADE FOUNDATION
MELANOMA RESEARCH FUND

SUPPORTING THE WORK
OF THE TRANSLATIONAL GENOMICS
RESEARCH INSTITUTE



ABOUT THE SHADE FOUNDATION MELANOMA RESEARCH FUND |

The Shade Foundation Melanoma Research Fund at TGen was established to give Shade Foundation donors an additional opportunity to fight melanoma by providing financial resources necessary to accelerate the rate of research in order to impact the way it is diagnosed and treated.

The Translational Genomics Research Institute (TGen) has begun an unprecedented and comprehensive genetic study that applies the newest and most sophisticated genomic technologies to prevent, detect, treat and ultimately eradicate melanoma. Since one of the most pressing needs for melanoma research is the availability of tissue samples that have been collected, stored and analyzed in a consistent manner, TGen is undertaking one of the most aggressive collection and analysis efforts of melanoma tumor samples to date, anywhere in the world. The genetic signatures yielded by the samples will provide scientists a framework for the development of new drugs, tailored to the individual.

TGEN'S MELANOMA RESEARCH |

Despite over 30 years of research, patients with advanced melanoma still have very few treatment options. TGen plans to change that by focusing on the genetic changes in skin cells that cause melanoma. This research will identify those genes that cause melanoma, and then turn that knowledge into diagnostic tests and therapies to benefit patients.

CURRENT RESEARCH | TGen is attacking familial and sporadic melanoma on multiple fronts. Drs. Jeffrey Trent, Pamela Pollock, Michael Bittner, Kevin Brown and their respective teams lead multiple studies designed to answer the most critical questions in melanoma research today. Their research efforts include:

- ♦ discovering how previously identified genes contribute to melanoma progression in normal melanocyte cells and what goes wrong to result in metastatic melanoma.
- ♦ launching a national genomic project that unites TGen and the H. Lee Moffitt Comprehensive Cancer Center in Tampa, Florida, to unravel the genetics of melanoma and develop new drugs based on newly discovered genetic knowledge about the disease.
- ♦ studying large numbers of patient samples in great molecular detail, improving our ability to detect melanoma and identify previously unknown drug targets.
- ♦ investigating a very specific 100-gene region to identify a familial melanoma-susceptibility gene.
- ♦ focusing on the molecular characterization of melanoma, from the earliest to the most advanced stages.



*Dr. Pamela Pollock
Associate Investigator
Head, Melanoma Research Lab*

